Streetbeat News

KRBP

Kiromic BioPharma Inc

https://kiromic.com/

Employees

50

Industry

Research and Development in Biotechnology

kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.

Open

1.08

Mkt cap

4M

Volume

7

High

1.50

P/E Ratio

-0.47

52-wk high

3.65

Low

1.08

Div yield

N/A

52-wk low

0.75

The SEC has charged Kiromic BioPharma and two former executives for misleading investors about FDA reviews of their cancer drug candidates, impacting their stock price.

Portfolio Pulse from

December 03, 2024 | 2:30 pm

Kiromic BioPharma's Deltacel therapy has received FDA Fast Track designation for treating metastatic non-small cell lung cancer. This designation aims to expedite the development and review process, potentially improving progression-free and overall survival for patients.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:07 pm

Several healthcare stocks experienced significant movement in Wednesday's after-market session. Notable gainers included Infinity Pharmaceuticals (INFI), TransCode Therapeutics (RNAZ), Longeveron Inc. - Subscription Right (LGVNR), Scinai Immunotherapeutics (SCNI), Avalo Therapeutics (AVTX), and NanoString Technologies (NSTG). On the other hand, Kiromic BioPharma (KRBP), OKYO Pharma (OKYO), Bionomics (BNOX), Impel Pharmaceuticals (IMPL), Creative Medical Tech (CELZ), and Joint (JYNT) saw declines.

Portfolio Pulse from Benzinga Insights

September 13, 2023 | 9:31 pm

On Tuesday, 164 companies hit new 52-week lows. Notable companies include NextEra Energy, SenesTech, WeWork, and Tarena International. The largest move was seen by WeWork, with shares plummeting 3189.55% to hit a new 52-week low. Tarena International's shares had the biggest turnaround, rebounding 0.0% after reaching a new 52-week low.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 5:34 pm

On Tuesday, 46 stocks hit new 52-week lows. The largest company by market cap to hit a new 52-week low was Moderna (NASDAQ:MRNA). The smallest firm by market cap to set a new 52-week low was American Rebel Holdings (NASDAQ:AREB). Polished.com (AMEX:POL) made the largest move down on the session, with shares plummeting 66.66% to reach its 52-week low. Brera Holdings (NASDAQ:BREA)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:08 am

During Friday's session, 59 companies set new 52-week lows. The largest firm by market cap to set a new low was Bristol-Myers Squibb (NYSE:BMY), while the smallest was BitNile Metaverse (NASDAQ:BNMV). Tonix Pharmaceuticals (NASDAQ:TNXP) saw the largest move with shares plummeting 38.2%. ClearPoint Neuro (NASDAQ:CLPT)'s stock bounced back the most, rising 0.0% after reaching its new low.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 4:36 pm

In Friday's mid-day session, several stocks saw significant movement. Addentax Group Corp. (ATXG) shares jumped 47.3% following the launch of an AI internet operational tools project with top Games-as-a-Service firms. Cineverse Corp. (CNVS) fell 17.8% after reporting weak Q4 sales. Other notable movers include CymaBay Therapeutics, Inc. (CBAY), Cyteir Therapeutics, Inc. (CYT), and Renalytix Plc (RNLX).

Portfolio Pulse from Lisa Levin

June 30, 2023 | 4:34 pm

During Friday's pre-market session, several health care stocks experienced significant movement. Renalytix, Cyteir Therapeutics, CymaBay Therapeutics, CytomX Therapeutics, Baudax Bio, and Alvotech saw their stocks rise, with Renalytix leading the gainers with a 38.6% increase. On the other hand, Unicycive Therapeutics, Surgalign Holdings, Ontrak, Kiromic BioPharma, InspireMD, and INVO Bioscience saw their stocks fall, with Unicycive Therapeutics leading the losers with a 24.2% decrease.

Portfolio Pulse from Benzinga Insights

June 30, 2023 | 1:12 pm

Renalytix Plc (RNLX) shares surged 48.7% in pre-market trading after receiving FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. Genfit S.A. (GNFT) shares gained 26.6% after positive results from Phase III ELATIVE® trial. Aurinia Pharmaceuticals Inc. (AUPH) shares rose 15.2% after the board announced exploration of strategic alternatives. Better Choice Company Inc. (BTTR) shares gained 15.2% after a $5 million investment from Alphia. Accolade, Inc. (ACCD) gained 12.2% after reporting better than expected Q1 earnings. iMedia Brands, Inc. (IMBIL) fell 18.1% in pre-market trading. Eco Wave Power Global AB (WAVE) fell 15.5% after announcing plans for a share repurchase program. Unicycive Therapeutics, Inc. (UNCY) fell 15.2% after an update on its marketing application.

Portfolio Pulse from Lisa Levin

June 30, 2023 | 12:12 pm

Kiromic Biopharma has appointed Brian Hungerford as its Interim CFO, according to an SEC filing. Hungerford brings extensive financial experience to the company.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 8:28 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.